MoonLake Immunotherapeutics (MLTX) Total Non-Current Liabilities (2021 - 2026)

MoonLake Immunotherapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $100.2 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 34.18% year-over-year to $100.2 million in Q1 2026; TTM through Mar 2026 was $100.2 million, a 34.18% increase from a year earlier, with the FY2025 full-year figure at $74.5 million, up 3482.2% from the prior year.
• Total Non-Current Liabilities improved to $100.2 million in Q1 2026 per MLTX's latest filing, from $74.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $100.2 million in Q1 2026 and bottomed at $4985.0 in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $2.6 million (2024), against an average of $25.9 million.
• Across the five-year window, Total Non-Current Liabilities soared 5285.82% in 2023 and plunged 32.57% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $411157.0 in 2022, then surged by 649.94% to $3.1 million in 2023, then sank by 32.57% to $2.1 million in 2024, then jumped by 3482.2% to $74.5 million in 2025, then surged by 34.59% to $100.2 million in 2026.
• Per Business Quant, the three latest MLTX Total Non-Current Liabilities figures stand at $100.2 million (Q1 2026), $74.5 million (Q4 2025), and $74.8 million (Q3 2025).